Veritas Pharma Inc is a Canada-based emerging pharmaceutical and Intellectual Property (IP) development company. The Company’s objective is, through its investment in Cannevert Therapeutics Ltd (CTL), to develop cannabis strains (cultivars) specific to chronic pain, such as cancer pain, nausea and vomiting, epilepsy, muscle spasms and Post-Traumatic Stress Disorder (PTSD), solving the critical need for clinical data to support medical marijuana claims. Veritas Pharma Inc’s commercial mission is to patent protect IP (cultivars and strains) and sell or license to cancer clinics, insurance industry and pharma. Its research and development approach objective is to solve the critical need for real science to support claims surrounding medical marijuana. Its scientific approach combined with its strategic alliances, addresses the concerns over the medical industry’s varied output in content, quality, potency and efficacy.